ArticleCritical care (London, England)2025
Norepinephrine exacerbates LPS-induced cardiomyopathy via SIRT3/HO-1 axis-mediated ferroptosis.
Article in Critical care (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Neuro-immune crosstalk in the tumor microenvironment: mechanisms and therapeutic implications for cancer immunotherapy.Journal of neuroinflammation · 2026Review
- The biphasic interactions between ferroptosis and oxidative stress: from molecular mechanisms to disease interventions.Molecular biology reports · 2026Review
- Cardiac Mitochondrial Dysfunction Following Bleomycin-Induced Acute Lung Injury in Rats.bioRxiv : the preprint server for biology · 2026Article
- Correction: Norepinephrine exacerbates LPS-induced cardiomyopathy via SIRT3/HO-1 axis-mediated ferroptosis.Critical care (London, England) · 2026Article
- Mitochondrial regulation of lactylation in sepsis-induced cardiomyopathy.Critical care (London, England) · 2025Review
- Mulberrin Alleviates Renal Ischemia-Reperfusion by Inhibiting Ferroptosis and Oxidative Stress Through Sirt3 Activation.Biomedicines · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
backgroundNorepinephrine (NE) is a first-line vasopressor for patients with septic shock, and its overuse can lead to "catecholamine adverse effects", including cardiovascular diseases. Lipopolysaccharide (LPS)-induced cardiomyopathy is one of the leading causes of mortality in septic patients. Previous studies have revealed that catecholamine can accentuate LPS-induced cardiomyopathy, but the underlying mechanisms remain elusive.
methodsAdult mice and H9c2 cells were exposed to LPS and NE. Structural changes, cardiac function and LDH assays were measured to verify the synergistic effects of LPS and NE in vivo and in vitro. Inhibitors of ferroptosis, heme oxygenase-1 (HO-1) and an activator of SIRT3 were used to reverse the synergistic effects. 4-hydroxynonenal (4-HNE)/MDA assays, immunofluorescence, transmission electron microscopy (TEM) and western blotting were used to measure ferroptosis in this study.
resultsIn our study, conventional dosage of NE exacerbated LPS-induced cardiomyopathy in long term, followed by ferroptotic alternations of ferrous iron, reactive oxygen species (ROS), mitochondria shrinkage, lipid peroxidation and HO-1 expression. In addition, inhibition of ferroptosis suppressed cardiomyocyte death and cardiomyopathy induced by LPS and NE, indicating the critical contribution of ferroptosis to cardiac injury via the synergistic effects of NE and LPS. Our recent study identified SIRT3 as a therapeutic target for cardiac ferroptosis. In line with this, overexpression of SIRT3 alleviated the death of cardiomyocytes treated with NE + LPS, accompanied by attenuated ferroptosis and HO-1 level. Moreover, the suppression of HO-1 by zinc protoporphyrin (ZnPP) also attenuated ferroptosis in cardiomyocytes treated with NE and LPS.
conclusionThese data strongly indicate that long-term use of NE can further develop LPS-induced cardiomyopathy via SIRT3/HO-1 axis-mediated ferroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.